Semaglutide and MASH: what ESSENCE found

Semaglutide now carries a liver indication. The US prescribing information for Wegovy lists the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, consistent with stages F2 to F3, in adults^[1]. A commentary in Drug Discovery Today, published on 10 August 2026, frames a separate national clearance in India as a turning point for the field^[2]. The claim rests on one trial, so it is worth reading what that trial measured before deciding what changed. Our semaglutide page covers the rest of the evidence base.

What MASH and MASLD mean in plain English

MASLD stands for metabolic dysfunction-associated steatotic liver disease. It describes fat building up in the liver in someone who also has at least one cardiometabolic risk factor, such as type 2 diabetes, overweight or obesity, raised blood pressure, or abnormal blood lipids^[3]. MASH is the inflamed version of that picture: the fat sits alongside liver cell injury, and over years the injury can lay down scar tissue. Pathologists stage that scarring from F0 (none) to F4 (cirrhosis).

Both acronyms are recent. A multisociety Delphi process involving 236 panelists from 56 countries replaced NAFLD with MASLD and NASH with MASH, partly on the grounds that the older words put people off. Sixty-six percent of respondents found the word "fatty" stigmatising and 61% said the same of "nonalcoholic"^[3]. If you read older coverage of semaglutide and the liver, it will use the NASH label for the same condition.

What the ESSENCE trial measured

ESSENCE is the Novo Nordisk phase 3 trial behind the indication. It randomised 1,197 patients with biopsy-defined MASH and fibrosis stage 2 or 3, in a 2:1 ratio, to once-weekly subcutaneous semaglutide at 2.4 mg or to placebo, for 240 weeks^[4]. The results published so far come from a planned interim analysis at week 72 covering the first 800 patients^[4]. That is the same molecule and the same weekly dose used in the obesity programme described on our semaglutide overview.

At week 72, steatohepatitis resolved without worsening of fibrosis in 62.9% of the 534 patients on semaglutide, against 34.3% of the 266 on placebo, an estimated difference of 28.7 percentage points (95% CI 21.1 to 36.2)^[4]. Fibrosis improved without worsening of steatohepatitis in 36.8% versus 22.4%, a difference of 14.4 percentage points (95% CI 7.5 to 21.3)^[4]. Both endpoints reached P less than 0.001. Mean body weight fell 10.5% on semaglutide and 2.0% on placebo. Gastrointestinal adverse events were more common in the semaglutide group, which matches the pattern set out on our semaglutide safety notes.

What ESSENCE has not shown

The placebo arm deserves attention. Roughly a third of placebo patients also cleared steatohepatitis on biopsy at 72 weeks^[4]. Some of that is the diet and activity advice both arms received, and some of it is the known variability in reading liver biopsies. It is also why a trial of this size was needed to separate the two groups at all.

The larger gap is the outcome that matters to patients. Cirrhosis-free survival is a separate primary endpoint for part 2 of ESSENCE, measured at week 240, and the trial registry lists estimated primary completion in April 2029^[5]. Nobody can yet say that semaglutide prevents cirrhosis, liver failure, transplant or death from liver disease. Improving what a pathologist sees down a microscope is a reasonable stand-in for those outcomes. It is not the same thing, and the open questions on our semaglutide page now include this one.

What one country's approval does and does not mean

Novo Nordisk India announced on 18 July 2026 that India's Central Drugs Standard Control Organisation had approved Wegovy for noncirrhotic MASH in adults with moderate to advanced liver fibrosis, alongside a reduced-calorie diet and increased physical activity^[6]. We could not read that clearance in a regulator document, so we are reporting it as a company announcement carried by trade press, not as a regulatory record we verified. The Drug Discovery Today commentary itself is indexed ahead of print with no abstract available, so its figures and its argument cannot be checked yet^[2].

A national approval binds one country. It does not change the legal status of semaglutide where you live, it does not make the product importable, and it does not create a prescribing route anywhere else. Semaglutide is prescription-only across the EU, EEA, UK and US, and the per-country detail sits in our semaglutide regulation notes. Among the incretin drugs we track, no liver indication appears on our tirzepatide or retatrutide pages.

Where this lands

MASH is now a condition with a licensed drug attached in some markets, which is a genuine change after years of failed candidates. The practical reading for a patient is narrow. If you have been told you have fatty liver plus a metabolic risk factor, this is a conversation for a hepatologist or your GP, not a reason to look for semaglutide outside a prescription. The US label still carries a boxed warning on thyroid C-cell tumours^[1], and the trial history, the discontinuation data and the running news log are on the main semaglutide page.

This article is educational and journalistic. It is not medical advice, and PeptideMethods does not advise on starting, stopping, dosing or obtaining any medicine. Decisions about liver disease belong with a healthcare provider who knows your history and can read your test results.